Rain Therapeutics Inc. (NASDAQ:RAIN) major shareholder Perceptive Advisors Llc sold 13,368 shares of the stock in a transaction that occurred on Thursday, October 7th. The stock was sold at an average price of $14.81, for a total value of $197,980.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Perceptive Advisors Llc also recently made the following trade(s):
- On Monday, October 11th, Perceptive Advisors Llc sold 21,826 shares of Rain Therapeutics stock. The stock was sold at an average price of $12.51, for a total value of $273,043.26.
RAIN traded up $1.51 during mid-day trading on Wednesday, reaching $15.06. The stock had a trading volume of 77,560 shares, compared to its average volume of 129,237. The stock has a fifty day moving average price of $16.12. Rain Therapeutics Inc. has a 52 week low of $11.57 and a 52 week high of $23.90.
A number of equities research analysts recently commented on RAIN shares. The Goldman Sachs Group lowered Rain Therapeutics to a “hold” rating and set a $22.00 price target on the stock. in a research report on Tuesday, September 14th. Zacks Investment Research upgraded Rain Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective on shares of Rain Therapeutics in a research report on Tuesday, July 20th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $25.25.
Hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC acquired a new position in shares of Rain Therapeutics in the 2nd quarter valued at $36,000. JPMorgan Chase & Co. acquired a new position in shares of Rain Therapeutics in the 2nd quarter valued at $44,000. Deutsche Bank AG acquired a new position in shares of Rain Therapeutics in the 2nd quarter valued at $68,000. Lumina Fund Management LLC acquired a new position in shares of Rain Therapeutics in the 2nd quarter valued at $93,000. Finally, Zimmer Partners LP acquired a new position in shares of Rain Therapeutics in the 2nd quarter valued at $155,000. 57.18% of the stock is currently owned by institutional investors.
About Rain Therapeutics
Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Rain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.